# Verdict: medulloblastoma.md

## 1. DOSE LEAK
None. Grepped for mg/Gy/mcg/AUC/cycle-numbers/q-schedules: zero hits. The only
numbers present are risk-stratification/epidemiology figures (age cutoffs "3
years"/"2 years", "1.5 cm" residual, "10 to 14 days" MRI-delay window, "20 to
30 percent" dissemination rate, "48 to 72 hours" post-op MRI window,
"roughly a third"/"up to a quarter" complication rates) — none are a
drug dose, radiation dose, or numbered chemo schedule.

## 2. UNGROUNDED CLAIMS
Cross-checked against DeVita 12th ed., Ch. 64 "Medulloblastoma" (Epidemiology
through Chemotherapy/long-term-effects, ~lines 241922-242434 of devita.txt).
Nearly everything traces cleanly (risk-group definitions, staging/MRI timing,
20-30% dissemination, surgery/GTR-vs-STR equivalence with adjuvant tx,
extent-of-resection-doesn't-matter-if-disseminated, ~25% posterior fossa
syndrome, IFRT-vs-PFRT non-inferiority, dose de-escalation hurting Group 4,
proton CSI benefits, <3yo radiation-avoidance strategies + COG P9934,
high-risk chemo drug-class buildout, recurrent-disease drug-class list,
"essentially incurable" relapse framing, 48-72h post-op MRI, IQ-decline-over-
a-decade pattern). Two spots are looser than the source:

- "Randomized comparisons of radiotherapy alone against radiotherapy plus
  chemotherapy established a survival benefit for adding chemotherapy" —
  DeVita's own text on the cited SIOP I trial (Tait et al.) says explicitly
  "there was no survival benefit from chemotherapy" as the headline result;
  only an unprespecified post-hoc subgroup analysis (T3/T4, STR patients)
  showed benefit, and the CCG comparison trial showed a DFS gap (59% vs 50%,
  55% vs 43%) rather than a proven OS benefit. DeVita's own conclusion
  ("routine use of chemotherapy for high-risk medulloblastomas has become
  standard") lands in the same place, but the sidecar's "established a
  survival benefit" overstates what the individual trial found. Minor
  overstatement, not a fabricated drug/regimen.
- "the trade-off is that omitting radiation in this age group has, in some
  trial data, come at the cost of worse disease control, and radiation
  delivery was the strongest positive prognostic factor in one such trial" —
  the DeVita trial being referenced here is explicitly a trial of
  **supratentorial PNETs** in children <3, not medulloblastoma. Medulloblastoma
  is a posterior-fossa tumor; supratentorial PNET is a related but distinct
  entity. The sidecar folds this into "this age group" (i.e., young
  medulloblastoma patients) without noting the cited trial's population was a
  different CNS tumor. Mild misattribution, worth a footnote if this draft
  moves to a stricter audience, not a fabrication of a drug/number.

No fabricated drug names, no invented trial acronyms, no invented statistics
— the two items above are overstatement/misattribution-of-source-population,
not the "% + regimen name I couldn't find at all" flavor of fabrication.

## 3. CITATION
Present: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles &
Practice of Oncology, 12th ed." — name only, no page numbers. Correct format.

## 4. Style check
No em-dash found (grepped for "—": zero hits).

## VERDICT: ISSUES (minor, non-blocking)
No dose leak, no invented drugs/trials/numbers, citation format correct.
The two items in section 2 are real but low-severity: one overstates a
trial's headline finding using the trial's own DeVita-adjacent (better) data
point, the other borrows a radiation-omission-risk data point from a
different-but-related CNS tumor (supratentorial PNET) and applies it to
medulloblastoma's "this age group" framing without flagging the source
population mismatch. Recommend R1 either soften "established a survival
benefit" to "was associated with improved DFS in the cited comparisons" and
add "(in a related pediatric CNS-PNET trial)" to the radiation-omission
sentence, or accept as-is if R1 judges the paraphrase level acceptable for a
management sidecar. Everything else is clean and ready.
